Search for: "Sanofi-Aventis US LLC" Results 21 - 40 of 84
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Aug 2009, 8:11 am
(patent infringement) 8/21: Aventis Pharama S.A., Sanofi-Aventis US LLC v. [read post]
1 Dec 2009, 9:45 am by Karen E. Keller
(patent infringement) 10/29: Aventis Pharma S.A. and Sanofi-Aventis US, LLC v. [read post]
28 Dec 2020, 7:04 am by Patricia O'Keefe
  A federal judge refused to narrow a class action lawsuit accusing Sanofi-Aventis US LLC of suppressing competing versions of its diabetes drug Lantus, rejecting the company’s claim that the named plaintiff, FWK Holdings LLC, lacked standing to challenge actions Sanofi took after FWK stopped buying the drug. [read post]
31 Aug 2010, 10:01 pm by Kelly
: Sanofi-Aventis v FDA, Sandoz (FDA Law Blog) (GenericsWeb)   Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
18 Aug 2017, 2:15 pm by Michael Sullivan
The Department of Justice announced the settlement on August 17, 2017, of two qui tam cases pending in the District of Massachusetts, United States, et al. ex rel. sanofi-aventis US LLC v. [read post]
18 Aug 2017, 2:15 pm by Michael Sullivan
The Department of Justice announced the settlement on August 17, 2017, of two qui tam cases pending in the District of Massachusetts, United States, et al. ex rel. sanofi-aventis US LLC v. [read post]
18 Aug 2017, 2:15 pm by Finch McCranie, LLP
The Department of Justice announced the settlement on August 17, 2017, of two qui tam cases pending in the District of Massachusetts, United States, et al. ex rel. sanofi-aventis US LLC v. [read post]
6 Oct 2010, 4:22 am by Kelly
Highlights this week included: Prezista (Darunavir) – US NIH becomes first patent holder to join UNITAID Medicines Patent Pool (IP Watch) (KEI) Taxotere (Docetaxel) – US: District Court finds Sanofi’s Taxotere invalid: Aventis v Hospira (Patent Docs) Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think… [read post]
24 Oct 2019, 9:24 am by Joe Mullin
A generic company recently invalidated a number of patents covering Lantus®—an insulin product that nets Sanofi-Aventis $15 million per day and has been the subject of numerous price hikes that far exceed inflation. [read post]
1 Apr 2010, 3:04 am
USPTO and Myriad Genetics (Docket Report) (Peter Zura's 271 Patent Blog) (Inventive Step) (Patently-O) (Holman's Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art) US: Study suggests USPTO erred in broad claims of Myriad BRCA1 patent (Tech Transfer Blog) (Patent Docs) US: CAFC confirms written description requirement in Ariad v Lilly (IP Law Blog) (IP Osgoode) (IP Spotlight) (Ars… [read post]
15 May 2011, 2:54 pm by FDABlog HPM
Karst –       Last week, the Federal Trade Commission (“FTC”) announced that the Commission’s Bureau of Competition (“Bureau”) sent letters (here, here, and here) to Sanofi-Aventis U.S. [read post]